From established players to up-and-coming firms, Canada’s pharmaceutical landscape is diverse and dynamic.
Three months into 2024, market watchers are keeping a close eye on pharma companies vying for the next major innovation.
Cipher Pharmaceuticals is a specialty pharmaceutical company with a diverse portfolio of treatments, including a range of dermatology and acute hospital care products. The company has out-licensed some of its offerings as well.
On March 14, the company released its full-year 2023 results, showing a 2.5 percent increase in gross profit compared to the previous year and EBITDA of US$12 million, consistent with fiscal year 2022. Following the report’s release, the share price surged 13.60 percent to C$8.10.
Year-on-year gain: 20.22 percent; market cap: C$4.34 billion; current share price: C$12.07
Bausch Health Companies, formerly Valeant Pharmaceuticals International, is one of the largest pharma companies in Canada. Its headquarters are in Laval, Quebéc, where the company has research and laboratory facilities equipped with state-of-the-art equipment and technology that play a crucial role in driving its research and development efforts.
Year-on-year gain: 11.91 percent; market cap: C$102.14 million; current share price: C$8.55
BioSyent Pharma is a specialty pharmaceutical company focused on improving patients’ lives by licensing and acquiring innovative pharmaceutical products that are proven safe and effective with a track record of improving patient outcomes. Its subsidiary, BioSyent Pharma, offers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Leave a Reply